Synopsis: Several stocks under Rs. 100 reported extraordinary Q3FY26 EPS growth up to 1,900 percent, driven by strong revenue gains, sequential profit improvements, and robust earnings momentum, signaling major turnarounds and profitability surges.
A rare surge in earnings has brought attention to stocks priced under Rs. 100, reporting an extraordinary EPS growth of up to 1,900 percent. Such a dramatic increase often signals a major turnaround, exceptional operational performance, or one-off gains. For investors, this kind of spike highlights both significant opportunity and potential risk, as rapid earnings growth in a low-priced stock can sharply influence market sentiment and trading activity. Listed below are stocks
Indsoya Limited
Apollo Ingredients Limited, based in Thane and incorporated in 1980, manufactures and trades oils, oil seeds, and oil-based products. Its offerings include health ingredients like botanical extracts, phytochemicals, and enzymes, as well as food ingredients such as probiotics. The company also cultivates oil seeds. Formerly known as Indsoya Limited, it was renamed Apollo Ingredients Limited in November 2023.
With a market capitalization of Rs. 10.56 crore, the shares of Indsoya Limited closed at Rs. 10.15 on Monday, up by 4.96 percent from its previous closing price of Rs. 9.67 per equity share.
Revenue for Q3FY26 stood at Rs. 2.77 crore, up from Rs. 1.09 crore in Q3FY25, marking a strong 154.1 percent YoY growth. Compared to Rs. 0.57 crore in Q2FY26, revenue grew sharply by 386.0 percent QoQ, showing a significant rebound from the previous quarter.
Profit for Q3FY26 came in at Rs. 0.87 crore, compared to Rs. 0.14 crore in Q3FY25, reflecting a robust 521.4 percent YoY growth. On a sequential basis, profit increased dramatically from Rs. 0.02 crore in Q2FY26, a 4,250 percent QoQ growth, indicating a major improvement in profitability.
Earnings per share (EPS) for Q3FY26 stood at Rs. 0.84, up from Rs. 0.13 in Q3FY25, marking a 546.2 percent YoY growth. Sequentially, EPS rose sharply from Rs. 0.02 in Q2FY26, a 4,100 percent QoQ increase, highlighting strong earnings growth alongside revenue expansion.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited, based in Ahmedabad and incorporated in 1993, manufactures and markets a wide range of pharmaceutical products in India and internationally. Its portfolio includes antibiotics (penicillin, cephalosporin), macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-emetic, cardiovascular, analgesic, sedatives, vitamins, and other therapeutic products.
With a market capitalization of Rs. 1,575.93 crore, the shares of Shukra Pharmaceuticals Limited closed at Rs. 35.99 on Monday, down by 3.87 percent from its previous closing price of Rs. 37.44 per equity share.
Revenue for Q3FY26 stood at Rs. 39 crore, compared to Rs. 11 crore in Q3FY25, reflecting a strong 254.5 percent YoY growth. On a sequential basis, revenue increased sharply by 550.0 percent QoQ from Rs. 6 crore in Q2FY26, indicating robust quarter-on-quarter improvement.
Profit for Q3FY26 came in at Rs. 20 crore, up from Rs. 3 crore in Q3FY25, marking a significant 566.7 percent YoY growth. Compared to Rs. 2 crore in Q2FY26, profit grew 900.0 percent QoQ, highlighting strong earnings momentum during the quarter.
Earnings per share (EPS) stood at Rs. 0.46 in Q3FY26 versus Rs. 0.07 in Q3FY25, showing a 557.1 percent YoY growth. Sequentially, EPS rose from Rs. 0.05 in Q2FY26, a 820.0 percent QoQ increase, reflecting substantial improvement in profitability alongside revenue growth.
PVV Infra Limited
PVV Infra Limited, based in Hyderabad and incorporated in 1995, provides infrastructure and construction services across India. It undertakes projects for multi-storied commercial and residential buildings, roads, bridges, airfields, duplex housing, and landscaping for EWS, low, middle, and high-income sectors.
With a market capitalization of Rs. 103.04 crore, the shares of PVV Infra Limited closed at Rs. 4.82 on Monday, down by 2.23 percent from its previous closing price of Rs. 4.93 per equity share.
Revenue for Q3FY26 stood at Rs. 16.24 crore, compared to Rs. 8.25 crore in Q3FY25, reflecting a strong 96.7 percent YoY growth. On a sequential basis, revenue increased by 48.5 percent QoQ from Rs. 10.93 crore in Q2FY26, indicating healthy improvement both year-on-year and quarter-on-quarter.
Profit for Q3FY26 came in at Rs. 4.21 crore, up from Rs. 0.12 crore in Q3FY25, marking a substantial 3,408.3 percent YoY growth. Compared to Rs. 2.11 crore in Q2FY26, profit doubled with a 99.5 percent QoQ increase, showing strong earnings momentum during the quarter.
Earnings per share (EPS) stood at Rs. 0.20 in Q3FY26 versus Rs. 0.01 in Q3FY25, a 1,900 percent YoY growth. Sequentially, EPS rose from Rs. 0.10 in Q2FY26, a 100 percent QoQ increase, reflecting significant improvement in profitability alongside revenue growth.
Bal Pharma Limited
Bal Pharma Limited, based in Bengaluru and incorporated in 1987, manufactures and markets pharmaceutical formulations and APIs in India and internationally. Its portfolio includes prescription drugs, generics, OTC products, intravenous infusions, and bulk drugs across therapeutic areas such as anti-infectives, pain management, respiratory care, women’s health, diabetes, cardiovascular, gastrointestinal, and herbal/ayurvedic products. Key brands include Aziwin, Balvibe, Diabend, Stonex, Secremet, and Servace.
With a market capitalization of Rs. 123.47 crore, the shares of Bal Pharma Limited closed at Rs. 77.55 per equity share, down by 0.36 percent from its previous closing price of Rs. 77.83 per equity share.
Revenue for Q3FY26 stood at Rs. 87.69 crore, compared to Rs. 73.15 crore in Q3FY25, reflecting a 19.9 percent YoY growth. On a sequential basis, revenue grew modestly by 18.5 percent QoQ from Rs. 74.02 crore in Q2FY26, indicating steady improvement both year-on-year and quarter-on-quarter.
Profit for Q3FY26 came in at Rs. 1.79 crore, up from Rs. 0.52 crore in Q3FY25, marking a 244.2 percent YoY growth. Sequentially, profit increased by 148.6 percent QoQ from Rs. 0.72 crore in Q2FY26, showing solid earnings momentum during the quarter.
Earnings per share (EPS) stood at Rs. 1.12 in Q3FY26 versus Rs. 0.30 in Q3FY25, a 273.3 percent YoY growth. Compared to Rs. 0.45 in Q2FY26, EPS rose 148.9 percent QoQ, reflecting strong improvement in profitability alongside steady revenue growth.
B.L.Kashyap & Sons Limited
B.L. Kashyap and Sons Limited, based in New Delhi and founded in 1978, is engaged in construction and infrastructure development across India. It undertakes projects for factories, IT campuses, commercial and residential complexes, retail spaces, and institutions. The company executes EPC projects for power plants, transmission and distribution systems, rail and metro systems, airports, hospitals, water and wastewater management, and industrial units.
With a market capitalization of Rs. 1,104.66 crore, the shares of B.L.Kashyap & Sons Limited closed at Rs. 49 on Monday, down by 1.96 percent from its previous closing price of Rs. 49.98 per equity share.
Revenue for Q3FY26 stood at Rs. 324 crore, up from Rs. 242 crore in Q3FY25, reflecting a 33.9 percent YoY growth. On a sequential basis, revenue declined by 8.7 percent QoQ from Rs. 355 crore in Q2FY26, indicating a slight slowdown compared to the previous quarter despite strong yearly growth.
Profit for Q3FY26 came in at Rs. 12 crore, compared to Rs. 1 crore in Q3FY25, marking a 1,100 percent YoY growth. Sequentially, the company turned around from a loss of Rs. 9 crore in Q2FY26, showing a strong recovery in earnings.
Earnings per share (EPS) stood at Rs. 0.52 in Q3FY26 versus Rs. 0.05 in Q3FY25, reflecting a 940 percent YoY growth. Compared to a negative EPS of Rs. 0.38 in Q2FY26, EPS improved sharply, highlighting a robust turnaround in profitability alongside stable revenue.
Singer India Limited
Singer India Limited, based in New Delhi and founded in 1851, manufactures and trades sewing machines, domestic appliances, and kitchen products in India. Its offerings include sewing machines (straight stitch, zigzag, embroidery, multi-needle, and industrial machines), kitchen appliances (mixer grinders, toasters, and gas stoves), and home appliances (irons, heaters, fans, washing machines, and refrigerators). The company markets products under the Singer and Merritt brands through showrooms, distributors, online platforms, and exports.
With a market capitalization of Rs. 449.53 crore, the shares of Singer India Limited closed at Rs. 72.25 on Monday, down by 1.78 percent from its previous closing price of Rs. 73.56 per equity share.
Revenue for Q3FY26 stood at Rs. 161.01 crore, up from Rs. 105.55 crore in Q3FY25, reflecting a 52.6 percent YoY growth. Compared to Rs. 137.90 crore in Q2FY26, revenue increased by 16.7 percent QoQ, indicating steady improvement both year-on-year and sequentially.
Profit for Q3FY26 came in at Rs. 5.39 crore, versus Rs. 1.51 crore in Q3FY25, marking a 257.0 percent YoY growth. Sequentially, profit rose 40.7 percent QoQ from Rs. 3.83 crore in Q2FY26, showing strong earnings momentum during the quarter.
Earnings per share (EPS) stood at Rs. 0.87 in Q3FY26, up from Rs. 0.24 in Q3FY25, reflecting a 262.5 percent YoY growth. Compared to Rs. 0.62 in Q2FY26, EPS increased 40.3 percent QoQ, highlighting consistent improvement in profitability alongside revenue growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
